These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 12852712)

  • 1. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia.
    Wunderink RG; Cammarata SK; Oliphant TH; Kollef MH;
    Clin Ther; 2003 Mar; 25(3):980-92. PubMed ID: 12852712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study.
    Rubinstein E; Cammarata S; Oliphant T; Wunderink R;
    Clin Infect Dis; 2001 Feb; 32(3):402-12. PubMed ID: 11170948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia.
    Wunderink RG; Rello J; Cammarata SK; Croos-Dabrera RV; Kollef MH
    Chest; 2003 Nov; 124(5):1789-97. PubMed ID: 14605050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin.
    Kollef MH; Rello J; Cammarata SK; Croos-Dabrera RV; Wunderink RG
    Intensive Care Med; 2004 Mar; 30(3):388-94. PubMed ID: 14714107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparison of linezolid and vancomycin in nosocomial pneumonia: results of the multicenter double-blind study].
    Grudinina SA; Zubkov MM; Krotova LA; Kurdiukova IuP; Kutsenko MA; Marinin VF; Sidorenko SV; Sinpal'nikov AI; Solomatin AS; Sterkhova GV; Fesenko OV; Fomina IG; Chuchalin AG
    Antibiot Khimioter; 2002; 47(1):12-7. PubMed ID: 12077934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study.
    Wunderink RG; Niederman MS; Kollef MH; Shorr AF; Kunkel MJ; Baruch A; McGee WT; Reisman A; Chastre J
    Clin Infect Dis; 2012 Mar; 54(5):621-9. PubMed ID: 22247123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Linezolid for the treatment of infections caused by Gram-positive pathogens in China.
    Lin DF; Zhang YY; Wu JF; Wang F; Zheng JC; Miao JZ; Zheng LY; Sheng RY; Zhou X; Shen HH; Ijzerman MM; Croos-Dabrera RV; Sheng W
    Int J Antimicrob Agents; 2008 Sep; 32(3):241-9. PubMed ID: 18635341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia.
    Awad SS; Rodriguez AH; Chuang YC; Marjanek Z; Pareigis AJ; Reis G; Scheeren TW; Sánchez AS; Zhou X; Saulay M; Engelhardt M
    Clin Infect Dis; 2014 Jul; 59(1):51-61. PubMed ID: 24723282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Vancomycin or linezolid as the treatment of choice for grampositive nosocomial pneumonia].
    Márquez-Peiró JF; Climente-Martí M; Jiménez-Torres NV
    Farm Hosp; 2009; 33(1):55-6. PubMed ID: 19401100
    [No Abstract]   [Full Text] [Related]  

  • 10. Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant gram-positive bacterial pathogens.
    Jantausch BA; Deville J; Adler S; Morfin MR; Lopez P; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
    Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S164-71. PubMed ID: 14520142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: comparative analysis of linezolid and vancomycin use.
    Nasraway SA; Shorr AF; Kuter DJ; O'Grady N; Le VH; Cammarata SK
    Clin Infect Dis; 2003 Dec; 37(12):1609-16. PubMed ID: 14689341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer.
    Jaksic B; Martinelli G; Perez-Oteyza J; Hartman CS; Leonard LB; Tack KJ
    Clin Infect Dis; 2006 Mar; 42(5):597-607. PubMed ID: 16447103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Linezolid versus vancomycin in the treatment of pneumonia caused by Gram-positive cocci: meta-analysis of randomised controlled trials].
    Lin ZQ; Huang YL; Huang P; Chen Q
    Zhonghua Jie He He Hu Xi Za Zhi; 2010 Dec; 33(12):900-6. PubMed ID: 21211409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of weight on treatment efficacy and safety in complicated skin and skin structure infections and nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
    Puzniak LA; Morrow LE; Huang DB; Barreto JN
    Clin Ther; 2013 Oct; 35(10):1557-70. PubMed ID: 24011955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: a systematic review and meta-analysis.
    Kalil AC; Murthy MH; Hermsen ED; Neto FK; Sun J; Rupp ME
    Crit Care Med; 2010 Sep; 38(9):1802-8. PubMed ID: 20639754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections.
    McKinnon PS; Sorensen SV; Liu LZ; Itani KM
    Ann Pharmacother; 2006 Jun; 40(6):1017-23. PubMed ID: 16720705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ZEPHyR study: a randomized comparison of linezolid and vancomycin for MRSA pneumonia.
    Chavanet P
    Med Mal Infect; 2013 Dec; 43(11-12):451-5. PubMed ID: 24238896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Linezolid and vancomycin for methicillin-resistant Staphylococcus aureus nosocomial pneumonia: the subtleties of subgroup analyses.
    Powers JH; Ross DB; Lin D; Soreth J
    Chest; 2004 Jul; 126(1):314-5; author reply 315-6. PubMed ID: 15249482
    [No Abstract]   [Full Text] [Related]  

  • 19. The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid.
    Stein GE; Wells EM
    Curr Med Res Opin; 2010 Mar; 26(3):571-88. PubMed ID: 20055750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: meta-analysis of randomised controlled trials.
    Jiang H; Tang RN; Wang J
    Eur J Clin Microbiol Infect Dis; 2013 Sep; 32(9):1121-8. PubMed ID: 23568605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.